Project Description

ExceptionHYAL® Jump

Happily moving

INGREDIENT BENEFITS

ExceptionHYAL® Jump is designed to support an active lifestyle by promoting an harmonic joint functionality. It improves joint lubrication and mobility, reducing pain and discomfort typically associated with osteoarthritis and joint inflammation.

Dosage: 200mg

Delivery forms: capsules, tablets, sachet/sticks, vials, drinks, syrups, drops

What is it?

ExceptionHYAL® Jump is a biotechnological ingredient belonging to the 2.0 generation Hyaluronans, based on a specific and selected spectrum of molecular weights, able to support the joint health and functionality.

What does it do?

ExceptionHYAL® Jump acts like a shock absorber by lubricating & plumping tissues, helping cushion effect which reduces joint stiffness.

It promotes the recovery of joint mobility and exerts such a lenitive effect on local inflammation to induce the reduction in the use of anti-pain drugs.

Mechanism of action

ExceptionHYAL® Jump promotes self-regeneration processes of tissues, boosting the natural HA synthesis.
It leads to the regeneration of endogenous synovial fluid.
This action combined with the anti-inflammatory performance promote the joint functionality and activity.

Available studies

  • Bioavailability
  • WOMAC, VAS and joint functionality improvement
  • Pain management
  • Modulation of anti-pain drugs use

Benefits

  • Joint care
  • Osteoarthritis management
  • Sport nutrition

INTERESTED IN FORMULATION SUPPORT?

Discover the Symphony capsule collection that provides customizable nutraceutical formulations addressing multiple health benefits.

Bibliography

  • Maltagliati A, Piangiolino C, Puoci F, “HA Tech 2.0 innovation in quality and efficacy control” Nutracos 2015
  • Masi S, “The 2.0 Full spectrum Hyaluronans technology to improve bioavailability and efficacy performance” (link)
  • Cicero AFG, Girolimetto N, Bentivenga C, Grandi E, Fogacci F, Borghi C. "Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. Diseases." 2020 Jul 8;8(3):26. doi: 10.3390/diseases8030026. PMID: 32650511; PMCID: PMC7564147. (link)